$ELTK

Eltek Slips To Loss In Q2; Shares Down

Eltek Ltd. (ELTK) reported a Q2 2026 net loss of $2.74 million, or $0.41 per share, versus a prior-year profit of $0.37 million, or $0.05 per share. Revenue fell to $11.53 million from $12.53 million. Adjusted EBITDA was a $1.93 million loss. Shares were down 6.39% to $8.45 on Nasdaq.

Original reporting
Published Aug 18, 2026, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 18, 2026, 3:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$ELTK
Bearish
high confidence
Mentioned
$ELTK
Relevance
6/10
alphai data visualization · based on rttnews.com
Decision brief

The 30-second read

$ELTKBearishMed
01

Why it matters

The disclosed net loss, adjusted EBITDA loss, and revenue decline are likely to affect near-term earnings expectations and valuation multiples.

02

Market read

A straightforward earnings miss with quantified losses and a same-day stock drop makes this a tradable catalyst for ELTK.

03

What to watch

The article lacks segment detail, guidance, backlog, and cash flow, so traders may be overreacting to headline profitability without knowing drivers.

Relevance 6/10Novelty 6/10Timing: reported Q2 results, with shares trading down 6.39% at $8.45

Background

Eltek Ltd. is a printed circuit board manufacturer; the article summarizes its Q2 2026 financial performance versus the prior year.

Company-level read

Ticker impact

$ELTKBearishHigh confidence
Context

Eltek reported a Q2 2026 net loss of $2.74M and revenue decline to $11.53M, with shares down 6.39% to $8.45.

Expected impact

Bearish bias for the next few sessions as traders digest the loss and revenue drop.

Evidence & confidence

The article provides concrete earnings datapoints (net loss, adjusted EBITDA loss, revenue down) and a same-day stock decline, indicating immediate market repricing.

Market effects

Weak PCB demand or margin pressure signals risk for electronics manufacturing supply chains, though this is company-specific.

Limited to Nasdaq-listed microcap sentiment unless broader industry weakness is indicated.

No direct global macro linkage beyond potential electronics supply-chain softness.

Counterpoint

The adjusted EBITDA loss is only slightly worse than the prior-year EBITDA, suggesting the deterioration may be incremental rather than a collapse.

Key entities

  • Eltek Ltd.

    Reported Q2 2026 net loss, adjusted EBITDA loss, and lower revenue; shares down on the news.

Related articles

$DHRMedAI 8/10

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.

$DHRMedAI 8/10

Danaher vs. Medtronic: Which Healthcare Recovery Story Has More Upside?

Danaher (DHR) and Medtronic (MDT) report recovery signs. DHR benefits from life sciences demand, with bioprocessing orders growing mid-teens. MDT shows highest annual revenue growth in 10 years, with Q4 revenue at $9.8B and FY26 at $36.4B. MDT's cardiac segment grew 78% globally, driven by cardiac ablation solutions. Both companies face challenges, with MDT's growth concentrated in a few platforms and DHR's revenue delayed into next year.

$TLRYMed

Tilray Posted Record Fiscal 2026 Revenue -- Why Isn't the Stock Rallying?

Tilray Brands reported record fiscal 2026 revenue of $915 million, up 11%, and adjusted EBITDA of $61.1 million, also up 11%. Adjusted net income nearly doubled to $12.2 million, but missed analyst estimates. GAAP net loss was $49.6 million. Management expects fiscal 2027 adjusted EBITDA of $68M-$75M. Cannabis sales represent 29% of total revenue.

$MDTMedAI 8/10

Medtronic vs. Tenet Healthcare: Which Healthcare Stock Offers Better Long-Term Growth?

Medtronic (MDT) and Tenet Healthcare (THC) present distinct growth prospects. MDT reported its highest annual revenue growth in a decade, driven by cardiac ablation solutions and investments in innovation. THC saw a 52.2% increase in adjusted EPS and 6.8% revenue growth, with margin expansion in hospitals. Investors must choose between MDT's innovation-led recovery and THC's operational improvements.

$PFEMedAI 8/10

Pfizer vs. Gilead: Which Drugmaker Has the Stronger Growth Story?

Pfizer (PFE) and Gilead (GILD) are compared on growth prospects. Pfizer's non-COVID revenue grew 5%, with key drugs like Padcev and Vyndaqel showing gains. Gilead's non-Veklury sales rose 10%, driven by HIV and oncology drugs. Both companies adjusted 2026 forecasts, with Gilead raising its outlook.